BC Week In Review | May 18, 2017
Clinical News

Keystone Nano begins Phase I of Ceramide NanoLiposome

In April, Keystone Nano Inc. (State College, Pa.) began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV Ceramide NanoLiposome in about 24 patients with advanced solid tumors. The primary endpoint of the trial...
Items per page:
1 - 1 of 1